, but increased levels of urine uric acid (39.23 ± 8.22 mg/L, p < 0.05) and urine creatinine (32.24 ± 1.69 mmol/L, p < 0.05) 
INTRODUCTION
Hyperuricemia is characterized by abnormally high levels of uric acid in the blood. In general, the upper end of the normal range is 360 µmol/L (6 mg/dL) for women and 416 µmol/L (7.0 mg/dL) for men.1 Hyperuricemia has also emerged as a metabolic disease which threatens human health, and is considered as an important risk factor for gout and may be associated with metabolic syndromes, stroke incidence, chronic kidney disease and cardiovascular disease [1, 2] . Current anti-hyperuricemic agents in use include: xanthine oxidase (XOD) inhibitors, which inhibit the activity of XOD, an enzyme involved in purine metabolism, of which allopurinol is the most often prescribed; uricosuric agents, which act on the proximal tubules in the kidneys to interfere with the absorption of uric acid from the urine back into the blood, and include probenecid, benzbromarone and sulfinpyrazone; and the enzyme urate oxidase, including the recombinant form rasburicase, which catalyzes the oxidation of uric acid to the more soluble allantoin which is more readily excreted via the kidneys [3] [4] [5] . However, these existing anti-hyperuricemic agents possess undesirable effects. For example, allopurinol, which is the drug of choice, has side effects including gastrointestinal irritation, bone marrow suppression, hypersensitivity syndromes, hepatitis and worsening renal function, which are unable to be tolerated by approximately 5 % of patients [6] . Uricosuric agents are used in patients with allopurinol-allergic syndromes as well as in under excreters with normal renal function and no history of urolithiasis. However, uricosuric agents, such as benzbromarone, also have issues. Though benzbromarone is still marketed in several countries by other drug companies, it was withdrawn by Sanofi-Synthélabo in 2003 after reports of serious hepatotoxicity. Similarly, the uricosuric agents probenecid and sulfinpyrazone have been reported to be nephrotoxic when used to treat hyperuricemia associated with moderate chronic renal insufficiency. Enzyme therapy using urate oxidase is only for treating severe hyperuricemia and is not widely used. Thus, anti-hyperuricemic agents have been limited in their clinical use due to their severe side effects. Therefore, it is important to search for alternative antihyperuricemic agents with more favorable toxicological profiles, and in particular from natural sources [7] .
Plantago depressa Willd. is widely used as a traditional Chinese herb for its efficiency in treating gouty diseases such as hyperuricemia, gout and inflammatory arthritis in China [8] [9] , but its actual mechanisms in the hypouricemic process remains unclear.
This study is to investigate therapeutic effects of PDWE on XOD activity and urate excretion in experimental hyperuricemia mice. Potassium oxonate was used to induce hyperuricemia in mice as previously reported [11, 12] . Sixty rats were divided into six groups of ten rats each: normal group, model group, allopurinol group, high dose, middle dose and low dose of PDWE groups. Model rats were treated with 250 mg/kg oxonate. Allopurinol group rats were treated with allopurinol (5 mg/kg); high dose, middle dose and low dose of of PDWE group rats were treated with 640 mg/kg, 320 mg/kg and 160 mg/kg PDWE respectively. Normal group rats and negative control group rats were administered water.
EXPERIMENTAL Plant material and extraction

Samples of
Except normal mice group, others were orally administered 250 mg/kg oxonate once daily for 7 consecutive days to induce hyperuricemia. The drugs (allopurinol and PDWE) were dispersed in water and were orally administered once daily from day 1 to day 10.
Biochemical analysis
After 10 days of treatment, animals were sacrificed by cervical vertebra. Blood samples were collected and centrifuged at 3500 × g for 20 min to obtain serum. The levels of XOD activities in serum and liver, serum and urinary levels of uric acid (UA), creatinine (Cr) and blood urea nitrogen (BUN) were determined by colorimetric methods using commercially available kits (purchased from Nanjing Jiancheng Biological Technology Co., Ltd., China) according to the manufacturers' instructions.
Data analysis
All statistics were analyzed using Statistical Package SPSS 18.0 (SPSS Inc, Illinois, Chicago, USA) and are expressed as mean ± standard error of mean (SEM), and analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's t-test. P < 0.05 was considered statistically significant.
RESULTS
Effect of PDWE on serum and urinary levels of UA, Cr, and BUN
The S UA level of model rats is significantly higher than those of normal rats after orally administered with potassium oxonate (p < 0.05). Over a period of 10 days of treatment, the S UA level was suppressed significantly (p < 0.05) by PDWE treatment at the dose of 160 -640 mg/kg, while the levels of U UA were increased significantly (p < 0.05) compared with model group (Table 1) . High dose of PDWE also had significant effects on serum and hepatic XOD activities in hyperuricemic mice as showed in Table 2 . Allopurinol at the dose of 5 mg/kg significantly suppressed hepatic XOD activity of hyperuricemic rats (p < 0.01). Compared with the normal group, the levels of BUN and S Cr were suppressed significantly (both p < 0.05) by PDWE treatments at a dose of 160 -640 mg/kg. Conversely, U Cr levels at the treated doses was approximately 3 times more than that of allopurinol at a dose of 5 mg/kg and approximately 4 times more than that of the model group. Although both S UA and U UA levels in PDWE-treated rats were higher than those in allopurinol-treated mice, PDWE dosedependently enhanced UA excretion.
DISCUSSION
Uric acid is the metabolism and is excreted in urine in humans, who have lost hepatic uricase activity during evolution. As a consequence, humans have higher serum uric acid levels compared with most mammals. Several factors including highprotein diet, alcohol consumption, high cell turnover, and renal failure, can result in elevated uric acid levels. In recent decades, hyperuricemia has received increasing attention as a major public health problem because of its high prevalence and the associated increases in the risk of hypertension, cardiovascular disease, diabetes and chronic kidney disease [11, 12] .
Some studies also demonstrated that traditional Chinese medicine could down-regulate hepatic XOD and enhance renal urate excretion in hyperuricemic mice [13] . However, in our clinical practice and previous reports, inhibitory effect of traditional Chinese medicine simiao pill on XOD was lower than that of allopurinol. Therefore, to reverse the complicated pathologic state of hyperuricemia in the early phase, PDWE was used to enhance renal urate excretion. Compared with model group, the levels of S UA were suppressed significantly by PDWE treatment at the dose of 160 -640 mg/kg, while the levels of U UA were increased significantly.
High dose of PDWE also had significant effects on serum and hepatic XOD activities in hyperuricemic mice. Increasing clinical reports have shown that hyperuricemia associated with an increasing risk of not only gout, but also chronic nephritis and [15] . Compared with the normal group, the levels of BUN and S Cr were suppressed significantly by PDWE treatments at a dose of 160 -640 mg/kg, and conversely, the degree of promotion of U Cr levels induced by PDWE at the treated doses was approximately 3 times more than that of allopurinol.
CONCLUSION
The findings of this study reveal that PDWE successfully treated hyperuricemic in rats by regulating renal urate transporters. Thus, the plant has the potential to be developed for clinical application in future.
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